Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Auransa to Receive Upfront Payment and be Eligible for Milestone Payments and Sales Royalties for Preclinical Program Identified by Company’s AI-Driven SMarTR™ Engine